• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    • Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders
    • The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250717183186/en/

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes.

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes.

    This year's Dexcom U roster welcomes 13 new athletes from colleges and universities across the country — including the University of Oregon, San Diego State University, and Northwestern University — representing 12 sports such as football, basketball, lacrosse, track & field, soccer, and more, alongside eight returning team members. The new athletes were selected following a dynamic, first-of-its-kind nationwide open call that drew over two hundred submissions, as Dexcom searched for the next great college athletes with diabetes to join the program.

    To officially welcome and celebrate the newly selected Dexcom U athletes, Dexcom hosted its Signing Day Camp earlier this month in Baltimore, Maryland. The event was hosted by Mark Andrews, Baltimore Ravens tight end and Dexcom Warrior, who relies on Dexcom G7 to manage his Type 1 diabetes and perform at the highest level. Mark was joined by Mike Golic Sr., NFL legend and sports broadcaster, who uses Stelo, Dexcom's over the counter glucose biosensor, to manage his Type 2 diabetes. The powerful, high-energy day brought together athletes with diabetes across all levels, including pro, college and youth sports, to redefine what's possible with diabetes. Both new and returning Dexcom U team members connected with Baltimore youth athletes and celebrated the resilience and determination that unite them.

    "It was incredibly inspiring to witness athletes of all ages come together at the Dexcom U Signing Day Camp to show what is possible while living with diabetes," said Mark Andrews, Dexcom Warrior and Baltimore Ravens tight end. "I know how impactful it would have been to have a support system like this in the early stages of my career, so for me, getting to be the role model I never had is really special."

    Dexcom U was created to elevate college athletes with diabetes who are breaking boundaries in sports and achieving their goals, despite their diagnosis. Since its inception in 2022, the program has directly impacted more than 40 college athletes across 38 schools and 19 sports. Each Dexcom U athlete relies on Dexcom continuous glucose monitoring (CGM) technology like Dexcom G7 to manage their diabetes with real-time data delivered directly to their smartphone or smartwatch,* empowering them to take control of their health and discover what they're made of.

    "This season, we set out to grow Dexcom U in ways that bring even more athletes into our Warrior community. From launching a new nationwide Open Call to hosting our first Dexcom U Signing Day Camp, we're creating impactful opportunities for athletes with diabetes to shine," said Leverne Marsh, executive vice president of marketing at Dexcom. "It's all part of our mission to show how Dexcom's continuous glucose monitoring technology supports performance, confidence, and connection."

    The 2025 Dexcom U roster consists of 21 athletes, with 13 new and eight returning team members, who all use Dexcom CGM to monitor their glucose levels and manage their diabetes:

    New athletes:

    • Ali Ramadan, Soccer, Creighton University
    • Anya Tribune, Soccer, Gardner-Webb University
    • Ari Long, Basketball, University of Oregon
    • Breanna Corral-Vargas, Acrobatics & Tumbling, Hawaii Pacific University
    • Clarke Byram, Track & Field, Pole Vault, University of Tennessee, Knoxville
    • Jackson Montgomery, Baseball, Coppin State University
    • Kya Epps, Track & Field, University of Cincinnati
    • Michael Trepeta, Lacrosse, Johns Hopkins University
    • Miles Byrd, Basketball, San Diego State University
    • Nadia Nemeth, Field Hockey, Northwestern University
    • Niamh Pfaff, Lacrosse, Yale University
    • Nikola Parichkov, Tennis, Wake Forest University
    • Patrick Heneghan, Football, Denison University

    Returning athletes:

    • Ben Mirisch, Water Polo, University of Southern California
    • Caleb Fauria, Football, University of Delaware
    • Isaac Traudt, Basketball, Creighton University
    • Jessica Walter, Softball, University of Connecticut
    • Madison Moraja, Track & Field, North Carolina State University
    • Nicholas Hahne, Cheerleading, University of Notre Dame
    • Raegan Lantz, Volleyball, Miami (OH) University
    • Shelomi Sanders, Basketball, Alabama A&M University

    Dexcom U athletes will receive access to Dexcom CGM, exclusive events and opportunities, and a supportive network of collegiate and professional athletes — including mentors like Seattle Sounders forward Jordan Morris and Dexcom U alum and Vegas Thrill setter Carly Graham — who support one another both on and off the field.

    To learn more about Dexcom U, visit www.Dexcom.com/DexcomU2025.

    About Dexcom

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Dexcom. Discover what you're made of. For more information, visit www.dexcom.com.

    *Smart device sold separately. For a list of compatible devices, visit www.Dexcom.com/compatibility.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250717183186/en/

    Media Contact

    Aly Brandt

    [email protected]

    Investor Contact

    Sean Christensen

    [email protected]

    Get the next $DXCM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    8/21/2025$100.00Buy
    Argus
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    7/26/2024$161.00 → $80.00Outperform → Neutral
    Robert W. Baird
    7/26/2024$145.00 → $75.00Overweight → Neutral
    JP Morgan
    More analyst ratings

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Argus initiated coverage on Dexcom with a new price target

    Argus initiated coverage of Dexcom with a rating of Buy and set a new price target of $100.00

    8/21/25 8:05:28 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Truist initiated coverage on Dexcom with a new price target

    Truist initiated coverage of Dexcom with a rating of Buy and set a new price target of $102.00

    6/16/25 7:46:45 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Goldman initiated coverage on Dexcom with a new price target

    Goldman initiated coverage of Dexcom with a rating of Buy and set a new price target of $104.00

    5/30/25 8:41:14 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dexcom Announces Upcoming Conference Presentations

    DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming investor conferences: The 2025 Wells Fargo Healthcare Conference on Wednesday, September 3, 2025 at 2:15 pm (EDT) The Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 2:00 pm (EDT) Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more th

    8/26/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of $221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024. S

    7/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Financal Officer Sylvain Jereme M sold $357,796 worth of shares (4,824 units at $74.17), decreasing direct ownership by 4% to 118,657 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    9/4/25 4:13:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    EVP, Chief Legal Officer Brown Michael Jon sold $40,145 worth of shares (500 units at $80.29), decreasing direct ownership by 0.53% to 94,102 units (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    8/18/25 5:56:28 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Director Foletta Mark G sold $222,903 worth of shares (2,750 units at $81.06) (SEC Form 4)

    4 - DEXCOM INC (0001093557) (Issuer)

    8/18/25 5:53:11 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    SEC Filings

    View All

    SEC Form 10-Q filed by DexCom Inc.

    10-Q - DEXCOM INC (0001093557) (Filer)

    7/30/25 5:19:57 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    DexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - DEXCOM INC (0001093557) (Filer)

    7/30/25 4:02:50 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by DexCom Inc.

    144 - DEXCOM INC (0001093557) (Subject)

    7/28/25 4:29:23 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    View All

    Synchron Expands Executive Team with Appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D

    Medical device leaders who have built and scaled category-defining products join Synchron to help drive its next-generation brain-computer interface platform as well as accelerate towards commercialization Synchron, a category-defining brain-computer interface (BCI) company, today announced the appointment of Andy Rasdal as Chief of Staff and Mark Brister as VP R&D. The appointments bring deep experience in launching and scaling category-leading medical devices, positioning Synchron to advance its Stentrode® BCI through U.S. clinical trials and prepare for global market entry. Mr. Rasdal, who joined Synchron's Board of Directors in 2023, will transition into a full-time executive role

    8/19/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

    Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

    7/17/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

    Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

    4/22/25 8:00:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Financials

    Live finance-specific insights

    View All

    Dexcom Reports Second Quarter 2025 Financial Results, Updates Full Year 2025 Guidance and Announces CEO Succession Plan

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights: Revenue grew 15% year-over-year to $1.157 billion on a reported basis and 15% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 16% on a reported basis and 14% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $212.6 million or 18.4% of revenue, an increase of 270 basis points compared to the second quarter of 2024. Non-GAAP operating income* of $221.8 million or 19.2% of reported revenue, a decrease of 30 basis points compared to the second quarter of 2024. S

    7/30/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

    7/1/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

    DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Qu

    5/1/25 4:02:00 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/13/24 5:02:33 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/23 11:16:37 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

    SC 13G/A - DEXCOM INC (0001093557) (Subject)

    2/9/22 3:43:37 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care